Neurological Biomarkers Market Size, Share, Growth Analysis, By Type(Genomic, Proteomic, Metabolomic, Imaging), By Application(Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder), By End User(Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, Research Organizations and Others), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35A2399 | Region: Global | Published Date: October, 2024
Pages: 157 |Tables: 63 |Figures: 75

Neurological Biomarkers Market Insights

Neurological Biomarkers Market size was valued at USD 6.13 Billion in 2022 and is poised to grow from USD 6.96 Billion in 2023 to USD 19.31 Billion by 2031, at a CAGR of 13.6% during the forecast period (2024-2031).

Neurological biomarkers are widely used for diagnosing a range of diseases such as autism, Parkinson’s disease, and depression. These biomarkers include metabolomics and imaging, genomic, and proteomic-based biomarkers. These biomarkers can be classified into metabolomics, imaging, genomics and proteomics. The biomarkers can be used for improving the treatment of neurological diseases, accelerate the development of drugs, allow for earlier diagnosis, and allow non-invasive testing. Moreover, pharmaceutical companies are receiving valuable information via digital biomarkers facilitating their clinical trial decision-making, further contributing to the neurological biomarkers market growth.

In the field of personalized medicine neurological biomarker research for neurodegenerative diseases is one of the fastest advancing fields. This evolution in precision medicine is significantly influencing the biopharmaceutical industry, leading to substantial transformations across various players, from biopharma to diagnostics companies, with roles ranging from commercial operations to research and development.  The market is likely to expand due to organizations offering funding at different levels of research, which is positively impacting the market. For instance, National Institutes of Health (NIH) has increased funding for health disparity research in Alzheimer's and brain aging, thus driving market growth.

US Neurological Biomarkers Market is poised to grow at a sustainable CAGR for the next forecast year.

Market Snapshot - 2024-2031

Global Market Size

USD 5.4 Billion

Largest Segment

Biomakre Validation and Testing

Fastest Growth

Biomarker Validation and Testing

Growth Rate

13.6% CAGR

Global Neurological Biomarkers Market ($ Bn)
Country Share for North America Region (%)

To get more reports on the above market click here to Buy The Report

Neurological Biomarkers Market Segmental Analysis

Global Neurological Biomarkers Market is segmented by Type, Application, End User and Region. Based on Type, the market is segmented into Genomic, Proteomic, Metabolomic, Imaging, Others. Based on Application, the market is segmented into Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder, Others. Based on End User, the market is segmented into Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, Research Organizations and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa

Neurological Biomarkers Market Analysis by Type 

Based on type, the proteomic biomarkers segment is dominating with the largest neurological biomarkers market share in 2023. Proteomic biomarkers are of great importance in the medical research and diagnostics field. The benefits of proteomic biomarkers help in the diagnosis of various kinds of cancers and understanding of disease pathogenesis. Proteomic biomarkers also assist in the discovery of non-invasive diagnostic biomarkers that may be identified in biological samples like urine or blood, helping to make the diagnostic process less frustrating for patients. Proteomic biomarkers may indicate both how a disease will progress and the response to specific treatments. Recognition of proteomic biomarkers contributes to the search for new therapeutic targets, which helps in creating better drugs. 

The others segment is witnessing the fastest growth with rapidly increasing neurological biomarkers market size during the forecast period. The other types consist of digital biomarkers, which is boosting market growth. Digital biomarkers help to facilitate better health management, resulting in minimizing the expense of clinical data extraction, and personalized remote caregiving. Wearable and mobile application technology are extremely helpful in constant health data monitoring from multiple sources, allowing patients to gain insights about their disorders resulting in enhanced health decision making. It enables physicians to provide individualized care remotely without patients having to visit the hospital or a doctor. These factors, in turn, assist the growth of other types of digital biomarkers and boost neurological biomarkers market. 

Neurological Biomarkers Market Analysis by Application 

Based on application, the Alzheimer's disease (AD) segment is dominating the neurological biomarkers market. This is because of an increase in incidences of Alzheimer's disease, clinical trials, and research activities on AD drug development. Biomarkers can help in diagnosis, show target engagement, support disease modification, and test for safety. The rapid growth of geriatric population who are more at risk for Alzheimer disease boosts the growth of the market. As per the Alzheimer’s Association, globally, almost 55 million people are suffering from dementia, and this number is expected to increase to 78 million by 2030 and near about 139 million by 2050. Furthermore, in the U.S., nearly 6.5 million people are estimated to live with Alzheimer disease. 

According to neurological biomarkers market analysis, the Parkinson’s disease segment is experiencing the fastest growth with a rapidly increasing market size. With augmenting biomarker R&D endeavors it is likely that new avenues will open for the development of Parkinson’s therapeutics. For instance, as per an article published in the Pharmaceutical Technology, in October 2022, a research study detected a novel cerebrospinal fluid biomarker for Parkinson’s disease. This has immensely improved the scope of potential drug targets. Hence, neurological biomarkers could potentially revolutionize the medical treatment of Parkinson's disease, and it is expected to be a key factor which will drive the market growth over time span. 

To get detailed analysis on other segments, Request For Free Sample Report

Neurological Biomarkers Market Regional Insights

The largest piece in the global neurological biomarkers market share is held by North America. This growth is mainly due to the well-established healthcare and research infrastructure in the region. The United States and Canada houses major pharmaceutical and biotechnology companies which provides them a competitive advantage in the research & development for new neurological biomarkers. Moreover, the renowned medical device players involved in neurobiology are also contributing to the regional growth market. The market growth is also supported by the initiatives from government bodies providing grants and funding for different neuroscience projects. Various U.S. and Canadian universities and academic institutions are collaborating with industry to develop new biomarkers. 

Asia Pacific is witnessing the fastest growth in the market. Factors such as the rapidly increasing disposable income in developing nations like India & China and rising prevalence of neurological disorders are fuelling the growth of the market. Furthermore, increasing geriatric population who are very prone to these diseases, coupled with a growing incidence of the target disease is also projected to drive regional neurological biomarkers market growth. The regional market is also benefitting from increased advancements R&D conducted by leading companies. For example, in June 2022, scientists from Hiroshima University and Kobe University developed a new blood test to diagnose Parkinson's disease. Additionally, researchers had utilized an inhibition assay P450 to detect alterations in Parkinson's disease.

Global Neurological Biomarkers Market By Geography
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Neurological Biomarkers Market Dynamics

Neurological Biomarkers Market Drivers

Increasing Prevalence of Cancer to Fuel Research on Biomarker 

  • As biomarkers are important indicators of various health or disease traits. Cancer goes through a multistage carcinogenesis procedure involving multiple events from various molecular pathways, which makes its diagnosis, prognosis and therapy extremely complicated. Due to this complexity, a single marker is insufficient. In addition, each cancer type has its unique molecular profile. Identification of new biomarkers leads to the development of targeted therapies that target dysregulation in cancer. The increasing prevalence of cancer will, in turn, stimulate biomarker research and thereby boosting the growth of neurological biomarkers market. 

Advancement in Precision Medicine 

  • Research related to biomarker in neurodegenerative disease is a growing field in the personalized medicine. Numerous molecules have been evaluated and linked to different neurodegenerative diseases. The evolution of precision medicine has influenced the biopharmaceutical industry widely. Many players from biopharma to diagnostics organizations with several functions, like research and development to commercial operations, will experience a massive transformation. This is expected to have a positive influence on the growth of the market. 

Restraints 

High Complexity of Data 

  • Biomarker research involves the integration of complex data sets, which is one of the major challenges to market growth. Biomarker data is varied, high-volume, and fast evolving. This is because it can be derived from thousands of different platforms including conventional blood tests, NGS, FISH testing, and more. Lack of standards to report these data, especially for NGS based tests presents a challenge for interpretation and aggregation across organizations adopting different methods. Furthermore, differences in biomarker testing throughout racial, ethnic, and economic groups further hamper data accessibility and completeness.  

High Complexity of Diseases and Virus Structure 

  • The inherent complexity and heterogeneity of diseases constitute a bottleneck in the development of biomarkers. Due to their diverse molecular pathways and presentations in the clinic, universal biomarkers are hard to identify. Disease heterogeneity makes this more difficult, as every patient has unique molecular signatures, making it challenging to find common biomarkers applicable across populations. Additionally, disease progression is extremely dynamic that needs biomarkers to adjust to the transforming conditions with time. These complexities hinder translating biomarker research into clinical practice, where biomarkers must precisely highlight the varied disease manifestations for efficient diagnosis, prognosis, and treatment monitoring.

Request Free Customization of this report to help us to meet your business objectives.

Neurological Biomarkers Market Competitive Landscape

The neurological biomarkers industry is experiencing the presence of many renowned, small and mid-sized players. This companies are dynamically engaging in providing consumables, software and services related to biomarker. These stakeholders are actively taking strategic initiatives to maintain their competitive edge through partnerships, clinical trials and seeking for investment opportunities. Market competition happens to be the critical, as new players are entering into market with strong focus on technology advancements and investing large amount of dollars to have a stronger foothold in this space.

Neurological Biomarkers Market Top Player’s Company Profile

  • Thermo Fisher Scientific Inc. 
  • Myriad Genetics, Inc. 
  • QIAGEN N.V.
  • Bio-Rad Laboratories, Inc. 
  • Merck KGaA 
  • F. Hoffmann-La Roche Ltd 
  • Bio-Techne Corporation 
  • Alector Inc. 
  • Banyan Biomarkers, Inc. 
  • Charles River Laboratories International, Inc. 
  • Cisbio 
  • C2N Diagnostics 
  • ImmunArray 
  • Euroimmun AG 
  • Cerebrospinal Fluid Diagnostics 
  • Abbott Laboratories

Neurological Biomarkers Market Recent Developments

  • In April 2024, Bill & Melinda Gates Foundation awarded a grant of USD 1.5 million to Owlstone Medical. This will help in the development of breath-based diagnostics and detect breath biomarkers for tuberculosis and human immunodeficiency virus.  
  • In October 2023, C2N Diagnostics launched an advanced fluid biomarker targeting neurofibrillary "Tau" tangle pathology in Alzheimer's disease. This is providing researchers a vital tool for monitoring disease progression by identifying Tau protein irregularities. 
  • In July 2023, Quanterix Corporation introduced LucentAD. This is a blood test using biomarkers to help in identifying Alzheimer’s disease in people.

Neurological Biomarkers Key Market Trends

  • Increasing Funds for Research: The rising presence of companies offering funds at several stages of research is boosting market growth. For example, the University of North Texas Health Science Center (HSC) was offered almost USD 45.5 million in funds from the National Institutes of Health (NIH). This fund will help in supporting research related to health disparities in Alzheimer's and brain aging. NIH is also offering additional funds for biomarkers research for the present study for Health and Aging Brain Among Latino Elders (HABLE). Therefore, this new trend is fueling market growth. 
  • Growing Development in Neurological Biomarkers Landscape: The latest advancements in biomarkers, like biomarker signatures increase the efficiency of treating neurological diseases. This has led to rapid drug development, non-invasive testing, and early diagnosis. Furthermore, digital biomarkers provide many pharmaceutical firms with supplemental information to accomplish clinical trial decisions. The National Institute of Neurological Disorders and Stroke is also offering funds, like advancement grants and cooperative agreements, for researchers conducting studies related to biomarker discovery, analytical validation, and clinical validation. 

Neurological Biomarkers Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. 

As per SkyQuest analysis, the neurological biomarkers industry is expected to experience positive growth over the forecast period. This is because of factors like growing prevalence of neurological disorders and rising research & development activities associated with neurological diseases. Moreover, growing adoption of imaging biomarkers and rising demand for minimally invasive testing is also positively influencing the market. Furthermore, current research to advance novel molecular biomarkers for neuropsychiatric conditions is offering immense opportunities for the market players. With the latest technological advancements, neurological biomarkers have emerged as possible diagnostic tools and their clinical utility is currently under active research globally.

Report Metric Details
Market size value in 2022 USD 6.13 Billion
Market size value in 2031 USD 19.31 Billion
Growth Rate 13.6%
Base year 2023
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Type
    • Genomic, Proteomic, Metabolomic, Imaging, Others
  • Application
    • Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder, Others
  • End User
    • Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, Research Organizations and Others
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Thermo Fisher Scientific Inc. 
  • Myriad Genetics, Inc. 
  • QIAGEN N.V.
  • Bio-Rad Laboratories, Inc. 
  • Merck KGaA 
  • F. Hoffmann-La Roche Ltd 
  • Bio-Techne Corporation 
  • Alector Inc. 
  • Banyan Biomarkers, Inc. 
  • Charles River Laboratories International, Inc. 
  • Cisbio 
  • C2N Diagnostics 
  • ImmunArray 
  • Euroimmun AG 
  • Cerebrospinal Fluid Diagnostics 
  • Abbott Laboratories
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Neurological Biomarkers Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Neurological Biomarkers Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Neurological Biomarkers Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Neurological Biomarkers Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Neurological Biomarkers Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Neurological Biomarkers Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW

REQUEST FOR SAMPLE

Want to customize this report?
REQUEST FREE CUSTOMIZATION

FAQs

Neurological Biomarkers Market size was valued at USD 6.13 Billion in 2022 and is poised to grow from USD 6.96 Billion in 2023 to USD 19.31 Billion by 2031, at a CAGR of 13.6% during the forecast period (2024-2031).

The neurological biomarkers industry is experiencing the presence of many renowned, small and mid-sized players. This companies are dynamically engaging in providing consumables, software and services related to biomarker. These stakeholders are actively taking strategic initiatives to maintain their competitive edge through partnerships, clinical trials and seeking for investment opportunities. Market competition happens to be the critical, as new players are entering into market with strong focus on technology advancements and investing large amount of dollars to have a stronger foothold in this space. 'Quanterix Corporation ', 'Thermo Fisher Scientific Inc. ', 'Myriad Genetics, Inc. ', 'QIAGEN N.V.', 'Bio-Rad Laboratories, Inc. ', 'Merck KGaA ', 'F. Hoffmann-La Roche Ltd ', 'Bio-Techne Corporation ', 'Alector Inc. ', 'Banyan Biomarkers, Inc. ', 'Charles River Laboratories International, Inc. ', 'Cisbio ', 'C2N Diagnostics ', 'ImmunArray ', 'Euroimmun AG ', 'Cerebrospinal Fluid Diagnostics ', 'Abbott Laboratories'

As biomarkers are important indicators of various health or disease traits. Cancer goes through a multistage carcinogenesis procedure involving multiple events from various molecular pathways, which makes its diagnosis, prognosis and therapy extremely complicated. Due to this complexity, a single marker is insufficient. In addition, each cancer type has its unique molecular profile. Identification of new biomarkers leads to the development of targeted therapies that target dysregulation in cancer. The increasing prevalence of cancer will, in turn, stimulate biomarker research and thereby boosting the growth of neurological biomarkers market. 

Increasing Funds for Research: The rising presence of companies offering funds at several stages of research is boosting market growth. For example, the University of North Texas Health Science Center (HSC) was offered almost USD 45.5 million in funds from the National Institutes of Health (NIH). This fund will help in supporting research related to health disparities in Alzheimer's and brain aging. NIH is also offering additional funds for biomarkers research for the present study for Health and Aging Brain Among Latino Elders (HABLE). Therefore, this new trend is fueling market growth. 

The largest piece in the global neurological biomarkers market share is held by North America. This growth is mainly due to the well-established healthcare and research infrastructure in the region. The United States and Canada houses major pharmaceutical and biotechnology companies which provides them a competitive advantage in the research & development for new neurological biomarkers. Moreover, the renowned medical device players involved in neurobiology are also contributing to the regional growth market. The market growth is also supported by the initiatives from government bodies providing grants and funding for different neuroscience projects. Various U.S. and Canadian universities and academic institutions are collaborating with industry to develop new biomarkers. 

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Neurological Biomarkers Market

Report ID: SQMIG35A2399

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE